Fortino Capital Partners has acquired a majority stake in Odin Group, a provider of IT solutions, cloud hosting, security, managed services and consultancy. No financial terms were disclosed.
Medicixi, a European life sciences investment firm, has closed its third fund at 400 million euros. The investors in Medicixi III include Novartis and Johnson & Johnson Innovation – JJDC, Inc. The fund will invest in early and late-stage biopharma companies.
Progressio has closed its third fund at a hard cap of 250 million euros, beating its target of 225 million euros. The private equity firm invests in Italian small to medium-sized businesses.
First Read closes the week with news that Generali buys Portuguese assets from Apollo for $674 mln, Toys ‘R’ Us is returning to the U.S. and President Trump says he’ll review lucrative Pentagon JEDI contract that will go to either Amazon or Microsoft.
Sierra Ventures, an early-stage tech venture firm, has closed its twelfth fund at $215 million. The fund’s limited partners include best endowments, pension funds and corporations.
Warburg Pincus and Kayne Anderson have agreed to provide WildFire Energy with an equity commitment exceeding $1 billion. Based in Houston, WildFire is an oil and gas exploitation and production company.
FlixMobility, the German parent company of global mobility platforms FlixBus and FlixTrain, has raised an undisclosed amount of Series F funding. TCV and Permira led the round. In addition to the funding, John Doran, a general partner at TCV, and Stefan Dziarski, a partner at Permira, will join FlixMobility’s board of directors.
Albireo Energy, which is backed by Huron Capital, has acquired Alabama Controls, a provider of building automation and HVAC control solutions as well as equipment and parts sales. No financial terms were disclosed.
Saugatuck Capital Company has made an investment in Harbor City, California-based Lunada Bay, a maker of handcrafted glass, ceramic and concrete tiles for the remodeling and architectural and design markets. No financial terms were disclosed.
Pacific Oak Capital LLC, a backer of commercial real estate-focused alternative investments programs, has named Michael Bender as chief financial officer. Bender’s work background include roles at Spirit Realty Capital Inc and Kamal Osman Jamjoom LLC.
California-based Haus, a co-investment platform for home ownership, has secured $7.1 million in seed funding. The investors included Montage Ventures, RIT Capital Partners and Tim Ferriss.
Gauge Capital has recapitalized Iselin, New Jersey-based Schlesinger Global LLC, a provider of market research solutions. No financial terms were disclosed for the transaction that was done in partnership with Schlesinger’s owners and management team.
Canadian cannabis extraction company Neptune Wellness Solutions has raised $41.4 million in a private placement. Perceptive Advisors was the lead investor. Cowen was the lead placement agent and sole U.S. placement agent while GMP Securities L.P. served as lead Canadian placement agent. Also Echelon Wealth Partners and Desjardins Securities acted as placement agents for Neptune.
Dublin, Ireland-based Cubic Telecom, a connectivity management supplier to the internet of things and automotive industries, has secured $26.4 million in funding. The backer was European Investment Bank.
Contentserv, a Swiss product experience platform, has secured an undisclosed amount of funding. The investor was Investcorp Technology Partners.
Phreesia, a patient intake management platform, has debuted its IPO after pricing its over 9.2 million shares at $18 per share. The stock began trading July 18, 2019 on the New York Stock Exchange under the ticker symbol “PHR.” J.P. Morgan, Wells Fargo Securities and William Blair are the lead underwriters. Phreesia’s pre-IPO backers included LLR Partners, HLM Venture Partners, Polaris Partners, Ascension Ventures, Echo Health Venture and Blue Cross Blue Shield Venture Partners.
Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol “MIRM.” Citigroup, Evercore ISI and Guggenheim Securities are the lead underwriters. Mirum’s pre-IPO backers included NEA, Deerfield Management, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.
Cambridge, Massachusetts-based Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has raised $72 million for its IPO after pricing its 4.5 million shares at $16 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol “FULC.” Morgan Stanley, BofA Merrill Lynch and SVB Leerink are the lead underwriters. Fulcrum’s pre-IPO backers included Third Rock Ventures and Foresite Capital.